Psychoses Clinical Trial
Official title:
DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics
The purpose of this study is to assess patients treated with the antipsychotics aripiprazole (Abilify®), olanzapine (Zyprexa®), quetiapine (Seroquel®), risperidone (Risperdal®), or ziprasidone (Geodon®) and to identify genetic variations more commonly found in individuals who develop diabetic metabolic signs and symptoms, which include changes in blood lipids, blood glucose, blood pressure, and body weight.
As many as 30% of psychiatric patients experience weight gain, central deposition of fat,
dyslipidemia, increased blood glucose and hypertension--diabetic metabolic symptoms--upon
treatment with atypical antipsychotic medication. As a result, cardiovascular disease risk
is significantly increased.
The long-term goal of this collaborative study is to identify, for each individual atypical
antipsychotic (AAP) medication, the gene variations associated with elevated risk of
diabetic metabolic symptoms (DiMS). If such genes are identified, in the future genetic
testing may help mental health care professionals choose treatment while minimizing the risk
of undesirable side effects of antipsychotics. We propose to develop a novel product termed
"Physiotype" to deliver personalized information for each patient on the drug specific risks
among aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone. The Physiotype
consists of a multi-gene ensemble of single nucleotide polymorphisms (SNPs) that,
interpreted with a biomathematical algorithm, may explain most of the inter-individual
differences in DiMS among the 5 AAPs. If this study does identify related genes, genetic
tests will be developed to provide patients and health care professionals with tools to
identify those patients who are at risk of developing adverse metabolic side effects to
antipsychotics.
;
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01196858 -
Duration of Untreated Psychosis (DUP) and Pathways to Care in Nordland
|
N/A | |
| Completed |
NCT00070889 -
Brain Cell Injury in Patients With A First Episode of Psychosis
|
N/A | |
| Completed |
NCT00159120 -
Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
|
Phase 4 | |
| Completed |
NCT00159133 -
Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
|
Phase 4 | |
| Completed |
NCT00087542 -
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
|
Phase 2 | |
| Completed |
NCT00095810 -
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
|
Phase 4 | |
| Completed |
NCT00469365 -
Pharmacy Interventions to Improve Chronic Disease Medication Refill
|
Phase 3 | |
| Completed |
NCT00491569 -
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
|
Phase 2 | |
| Completed |
NCT00204061 -
Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
|
Phase 4 | |
| Completed |
NCT00328276 -
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
|
Phase 2 | |
| Withdrawn |
NCT00276263 -
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
|
Phase 2 | |
| Active, not recruiting |
NCT00260273 -
Access, Detection and Psychological Treatments
|
N/A | |
| Completed |
NCT00960219 -
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
|
Phase 2 | |
| Completed |
NCT03609515 -
Patient-controlled Admissions in Inpatient Mental Health Services
|
N/A |